Interleukin 1 (IL-1) possesses as an intercellular signal a wide spectrum of inflammatory, metabolic, haematopoetic, immunological, and reparative properties and can be a mediator not only ofhost defence but also of disease. Reduction of IL-1 can decrease the inflammatory host response. A human recombinant IL-1 receptor antagonist (IL-Ira) was used to block IL-1 after intraocular lens implantation in rabbits. Seventeen rabbits underwent intercapsular phacoemulsification and posterior chamber lens implantation. A 100 ig dose (0.1 ml) of IL-lra (1 mg/ml) was injected into the anterior chamber at the end of surgery in seven rabbits. The 10 rabbits serving as the controls received no IL-lra. Postoperatively, all rabbits were observed with a slit-lamp, and the aqueous flare intensity was measured with a laser flare cell meter at 12 hours, 1, 2, 3, and 4 days and thereafter at 1, 2, 3, and 4 weeks. Aqueous flare intensity was significantly lower on days 2 and 3, and fibrin deposition much less marked in the eyes treated with IL-Ira, compared with the controls. The results suggest that IL-1 is involved in the postoperative inflammation that occurs after intraocular lens implantation and the use of the IL-lra would be valuable forreducing this problem. (BrJf Ophthalmol 1994; 78: 917-920) 
The cytokine interleukin 1 (IL-1) functions as an intercellular signal and regulates locally and, at times, systemically the immunological, inflammatory, and reparative host response to injury.' The current studies with recombinant IL-1 in human subjects revealed that IL-1 can be a mediator not only of host defence but also of disease. Its over or prolonged production in either situation, however, will diminish or even impair the normal host functions. Therefore, control of IL-I synthesis or its effects becomes a target of therapy in many diseases. 2 In the ophthalmic field, the intravitreal injection of IL-I is known to cause 9 Interleukin 1 was detected in the subretinal fluid of retinal detachment in humans,'" in the vitreous of patients with proliferative diabetic retinopathy," and in the aqueous humour following intraocular lens implantation in rabbits. 2 Interleukin 1 receptor antagonist (IL-lra) has recently been identified as the first described naturally occurring, endogenous receptor antagonist ofany cytokine. It has a molecular weight of 17000-25000 and inhibits IL-1 activities by competitive binding to a specific receptor."' It is produced by monocytes, macrophages, neutrophils, fibroblasts, keratinocytes, and other epithelial cells."' It has been shown in various animal models of disease'5 16 as well as in humans'7-'9 to block the activity of IL-1. It effectively reduced the inflammatory response of anterior uveitis caused by intravitreal injection of IL-i 20 IL-ira may be effective for reducing postoperative inflammation after intraocular lens implantation.
We performed an experiment in rabbits to examine whether IL-lra is effective in reducing postoperative inflammation after cataract surgery.
Materials and methods

SURGICAL PROCEDURE
Seventeen rabbits weighing 1i5 to 2 kg were anaesthetised by the ketamine hydrochloride (5 mg/kg) and xylazine hydrochloride (2 mg/kg). Before surgery the pupil of the rabbit used was dilated with 1-0% tropicamide and 2 5% phenylephrine. Surgery was performed on one eye only. Intercapsular phacoemulsification following a small upper linear anterior capsulotomy was performed. To each 500 ml of balanced salt solution (Alcon Inc, Fort Worth, Texas, USA), 1 ml ofadrenaline hydrochloride at a concentration of 1 mg/ml and 1000 units of sodium heparin were added to facilitate pupillary dilatation and reduce the fibrinous reaction during surgery. After a posterior chamber lens with modified C loop and 6-5 mm optic was implanted, the axial anterior capsule was removed in such a manner so that the remaining anterior capsule covered the intraocular lens margin.
A 0-I ml aliquot (100 rig) of human recombinant IL-Ira, (Ohtsuka Pharmaceutical, Tokushima, Japan, 1 mg/ml) was injected into the anterior chamber at the end of surgery in seven rabbits, and 0-1 ml of BSS was injected into 10 (Fig 1) .
SLIT-LAMP EXAMINATION
Fibrin deposition was seen in every control eye on days 1-4, and it needed 2 to 4 weeks to disappear. In contrast with the untreated eyes, fibrin deposition was much less marked and appeared later in the treated eyes, as determined by the slit-lamp examination.
All control eyes showed obvious secondary cataract formation with capsular opacification and synechiae on slit-lamp examination 6 months after surgery. Red reflex from the fundus could hardly be detected. Two of seven treated eyes showed obviously less secondary cataract formation and less capsular opacification, so that the red reflex was evident. We submitted these two eyes and one control eye chosen randomly, to histopathological examination to observe specifically the capsular bag in those eyes.
HISTOPATHOLOGICAL EXAMINATION
In the capsular bag of the two treated eyes, LEC proliferation was generally much less marked than that in the control eye. In the former, a few lens epithelial cells were observed on the posterior capsule, whereas lens epithelial cells were thickly layered in the latter. Discussion Though our results are based only on one experiment, they showed that human IL-Ira decreased postoperative inflammation after intraocular lens implantation in the rabbit eye when it was injected into the anterior chamber at the end of surgery. Its significant (decreasing) effect on aqueous flare intensity was manifested after 2 to 3 days. The gradual increase in flare intensity thereafter suggests that IL-ira disappeared gradually. IL-Ira may have been metabolised or cleared in those eyes.
Yokoyama'2 reported that the IL-1 B concentration in the anterior chamber at day 7 after intraocular lens implantation in rabbits was 10 12 (SD 3 96) ng/ml aqueous humour; Rosenbaum et a120 injected 75 tg of human recombinant IL-lra intravitreally in rabbit eyes to assess the potential activity of the IL-Ira in ocular inflammation induced by the intravitreal injection of IL-1. In the present study, we chose the dose of IL-Ira, because it appeared sufficient to block IL-I in the anterior chamber of the rabbit and, therefore, to assess the effect.
Even though the IL-Ira used was the human antagonist, it effectively blocked IL-1 in the rabbit eye. There are parallel results20 that During several acute or chronic diseases, the effect of specific blocking of IL-I has not yet been completely clarified. Rosenbaum and coworkers20 reported that IL-Ira was effective in reducing IL-1 induced inflammation in rabbit eyes, but did not produce a significant reduction in inflammation subsequent to an active Arthus reaction or the intravitreal application of endotoxin. A parallel result'9 was reported that intraventricular injection of IL-Ira attenuated the febrile response to a subsequent intracerebroventricular bolus ofIL-1, but had no effect on the response to the endotoxin. Prostaglandin E2 (PGE2) plays a major role in postoperative inflammation after intraocular lens (IOL) implantation.2627 The effect of IL-ira in the present study may be accounted for by the blockage of IL-I that stimulates PGE2 synthesis by activating the arachidonic acid cascade.28`0 Recent reports3"3-showed that IL-Ira inhibits the production and effects ofPGE2. This can be supported by the fact that inhibitors of eicosanoid synthesis inhibited the ocular inflammatory effects of exogenous IL-1 ca.5 However, Kulkarni and In conclusion, the present study suggests that IL-1 is involved in postoperative inflammation after intraocular lens implantation, and IL-Ira seems to be valuable for decreasing surgically induced inflammation in the rabbit eye. Determining of the role of cytokines in ocular inflammation may lead to new treatments for the control of the effects of these important mediators.
